OliX Pharmaceuticals Inc. announced that the U.S. Food and Drug Administration (FDA) has approved the Company's Investigational New Drug (IND) application to develop OLX10212 for the treatment of age-related macular degeneration (AMD). OLX10212 targets inflammation pathways that play a key role in the development of geographic atrophy (GA) and neovascular AMD. The primary objective of the upcoming phase 1 program is to evaluate the safety and tolerability of OLX10212 in patients with AMD.

With the FDA approval of the IND application for OLX10212, the Company has entered clinical trials for two investigational therapeutic programs in the U.S. In June 2022, the Company completed patient enrollment of the Phase 2a clinical trial of OLX10010, for the treatment of hypertrophic scarring.